Monique J. Roobol
Erasmus University Medical Center
432 Papers
3K Citations
Monique J. Roobol is an academic researcher from Erasmus University Medical Center. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 64, co-authored 432 publications. Previous affiliations of Monique J. Roobol include Erasmus University Rotterdam.
Chat about Author
Papers
A comment on prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
TL;DR: Comment on the first four rounds of screening in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) screening trial allows a direct comparison with data obtained in the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial.
9
Is Prostate Cancer Screening Bad or Good? Summary of a Debate at the Innovation in Urology Meeting, September 17–19, 2010, Milan, Italy
TL;DR: The ongoing discussion of whether prostate-specific antigen (PSA)–based screening for PCa should become part of general health care has increased again, driven by new arguments.
9
Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic
TL;DR: In more than three-quarters of men referred for prostate biopsy, the suspicion of PCa was confirmed and almost half of men had clinically significant PCa (GS ≥3+4 PCa), showing a huge potential for multivariable risk-stratification in primary care.
Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men
TL;DR: The A-ERSPC-RC3 accurately predict the prostate biopsy in a contemporary Chinese multi-center clinical cohort and the CPCC-RC can predict accurately in a population-based screening cohort, but not in the European clinical cohort.
Single Prostatic Cancer Foci on Prostate Biopsy
Theodorus H. van der Kwast,Theodorus H. van der Kwast,Tineke Wolters,Andrew Evans,Monique J. Roobol +4 more
TL;DR: Urologists should be aware of a potential variation in the pathologist's threshold to call a cancer despite the introduction of helpful ancillary techniques, as well as finding means to differentiate between indolent and more aggressive cancers.
9